NTRA ▼ -0.2% - Natera, Inc. $NTRA Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera shares dipped 0.2% despite the company announcing that its Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer. The modest decline suggests investors may be digesting the news cautiously, perhaps viewing the Japan approval as incremental rather than transformative to near-term revenues, or reflecting broader market conditions outweighing the positive regulatory milestone. 22-SEP-2026 08:01 AM ET